Cargando…
Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. ME...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718016/ https://www.ncbi.nlm.nih.gov/pubmed/26714738 http://dx.doi.org/10.1186/s13075-015-0894-9 |
_version_ | 1782410722990358528 |
---|---|
author | Golinski, Marie-Laure Vandhuick, Thibault Derambure, Céline Fréret, Manuel Lecuyer, Matthieu Guillou, Clément Hiron, Martine Boyer, Olivier Le Loët, Xavier Vittecoq, Olivier Lequerré, Thierry |
author_facet | Golinski, Marie-Laure Vandhuick, Thibault Derambure, Céline Fréret, Manuel Lecuyer, Matthieu Guillou, Clément Hiron, Martine Boyer, Olivier Le Loët, Xavier Vittecoq, Olivier Lequerré, Thierry |
author_sort | Golinski, Marie-Laure |
collection | PubMed |
description | BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. METHODS: RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNFα inhibitors. T and B cells from healthy controls (HC) were cultured with TNFα, and TNFα receptors neutralizing antibodies to highlight the TNFα effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively analyzed using the Proteome Profiler arrays and flow cytometry. RESULTS: In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was downregulated under TNFα inhibitors and upregulated under TNFα. In T cells from RA patients, RasGRP1 was decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNFα stimulation increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments have confirmed that the TNFα effect observed on T cells proliferation was due to the decrease of RasGRP1 expression. Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNFα and in B cells from HC leading us to conclude that RasGRP3 in B cells was modulated by TNFα. CONCLUSION: This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a biomarker linked to TNFα inhibitors. After binding to TNFR1, TNFα reduced RasGRP1 protein expression resulting in inhibition of T cell activation. TRIAL REGISTRATION: Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October 2005. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0894-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4718016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47180162016-01-20 Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors Golinski, Marie-Laure Vandhuick, Thibault Derambure, Céline Fréret, Manuel Lecuyer, Matthieu Guillou, Clément Hiron, Martine Boyer, Olivier Le Loët, Xavier Vittecoq, Olivier Lequerré, Thierry Arthritis Res Ther Research Article BACKGROUND: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness, leading to the question of RasGRP1 and RasGRP3 involvement in RA. METHODS: RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNFα inhibitors. T and B cells from healthy controls (HC) were cultured with TNFα, and TNFα receptors neutralizing antibodies to highlight the TNFα effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively analyzed using the Proteome Profiler arrays and flow cytometry. RESULTS: In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was downregulated under TNFα inhibitors and upregulated under TNFα. In T cells from RA patients, RasGRP1 was decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNFα stimulation increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments have confirmed that the TNFα effect observed on T cells proliferation was due to the decrease of RasGRP1 expression. Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNFα and in B cells from HC leading us to conclude that RasGRP3 in B cells was modulated by TNFα. CONCLUSION: This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a biomarker linked to TNFα inhibitors. After binding to TNFR1, TNFα reduced RasGRP1 protein expression resulting in inhibition of T cell activation. TRIAL REGISTRATION: Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October 2005. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0894-9) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-26 2015 /pmc/articles/PMC4718016/ /pubmed/26714738 http://dx.doi.org/10.1186/s13075-015-0894-9 Text en © Golinski et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Golinski, Marie-Laure Vandhuick, Thibault Derambure, Céline Fréret, Manuel Lecuyer, Matthieu Guillou, Clément Hiron, Martine Boyer, Olivier Le Loët, Xavier Vittecoq, Olivier Lequerré, Thierry Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title | Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title_full | Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title_fullStr | Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title_full_unstemmed | Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title_short | Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors |
title_sort | dysregulation of rasgrp1 in rheumatoid arthritis and modulation of rasgrp3 as a biomarker of tnfα inhibitors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718016/ https://www.ncbi.nlm.nih.gov/pubmed/26714738 http://dx.doi.org/10.1186/s13075-015-0894-9 |
work_keys_str_mv | AT golinskimarielaure dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT vandhuickthibault dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT derambureceline dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT freretmanuel dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT lecuyermatthieu dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT guillouclement dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT hironmartine dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT boyerolivier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT leloetxavier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT vittecoqolivier dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors AT lequerrethierry dysregulationofrasgrp1inrheumatoidarthritisandmodulationofrasgrp3asabiomarkeroftnfainhibitors |